FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD Using Personalized Brain Mapping
Wave Neuroscience's magnetic stimulation system achieved 68% remission in preliminary trials, offering new hope for millions struggling with post-traumatic stress disorder.
The FDA has cleared a groundbreaking approach to treating post-traumatic stress disorder that combines brain mapping, artificial intelligence, and magnetic stimulation to deliver personalized therapy without medication. Wave Neuroscience's Magnetic e-Resonance Therapy (MeRT) system represents the first FDA-cleared nonmedication treatment specifically designed for PTSD, offering new hope for millions who struggle with current pharmaceutical options.
The clearance arrives at a critical moment: approximately 17.5 U.S. veterans die by suicide daily, with 7% of veterans diagnosed with PTSD annually and 6% lifetime prevalence in the general population. An estimated 13 million people in the U.S. may be eligible for this treatment.
How the Technology Works
MeRT combines electroencephalogram (EEG) brain mapping with transcranial magnetic stimulation (TMS), using what Wave Neuroscience describes as an "augmented AI-derived multivariate algorithm" to personalize treatment protocols for each patient. Unlike one-size-fits-all approaches, the system analyzes individual brain activity patterns to tailor magnetic stimulation parameters.
Developed in collaboration with researchers at Texas A&M Health, the treatment protocol involves five sessions weekly for 5-6 weeks. According to the company, beneficial effects continued even after treatment concluded, suggesting lasting neurological changes rather than temporary symptom suppression.
Clinical Trial Results
Preliminary clinical trial results reported by Wave Neuroscience demonstrated a 52% reduction in PTSD symptoms and a 68% remission rate. The clinical findings are still being prepared for public dissemination, according to the source announcement.
In contrast, a 2020 review found that standard SSRI medications (sertraline and fluoxetine)—the only two FDA-approved medications for PTSD—show symptom improvements of just 6.8-10.1 points and achieve maximum remission rates of only 10.9%.
The technology offers an alternative for patients who don't respond to SSRIs, cannot tolerate medication side effects, or drop out of psychotherapy due to its anxiety-provoking nature. According to the research brief, this objective, data-driven approach may reduce treatment trial-and-error and improve patient engagement by providing visible brain activity measurements.
Dr. Kenneth S. Ramos of Texas A&M Health Institute of Biosciences and Technology collaborated on the development alongside Wave Neuroscience's medical team, including Chief Medical Officer Dr. Erik Won, lead psychiatrist Dr. Israel Liberzon, and Chief Scientific Officer Dr. Leslie S. Prichep.
Regulatory Pathway and Future Plans
Wave Neuroscience received FDA breakthrough device designation in 2024, enabling an accelerated review process while maintaining scientific and medical standards. The company completed the clearance process in just over two years—dramatically faster than the typical decade-long timeline for medical devices.
Wave Neuroscience is currently negotiating insurance coverage to improve accessibility for the estimated 13 million eligible Americans. The company has indicated potential expansion plans to address depression and anxiety, representing significant market opportunities beyond PTSD treatment.
Sources
Reporting & accountability
How we maintain accuracy
Health AI Central separates reported facts, analysis, and public-source data. Readers can review our standards, request a correction, or consult the relevant research methodology before relying on a claim.